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Optimal sedation and analgesia are of key importance in intensive care. The aim of this study was to assess the quality of
sedoanalgesia and outcome parameters in regimens containing midazolam and either fentanyl or remifentanil. A prospective,
randomized, open-label, controlled trial was carried out in the ICU unit of a large teaching hospital in Istanbul over a 9-month
period. Thirty-four patients were randomly allocated to receive either a remifentanil-midazolam regimen (R group, n = 17) or a
fentanyl-midazolam regimen (F group, n = 17). A strong correlation between Riker Sedation-Agitation Scale (SAS) and Ramsey
Scale (RS) measurements was observed. Comparatively, remifentanil provided signiﬁcantlymore potent and rapid analgesiabased
on Behavioral-PhysiologicalScale (BPS) measurements and a statistically nonsigniﬁcantlyshorter time to discharge. On the other
hand, remifentanil also caused a signiﬁcantly sharper fall in heart rate within the ﬁrst six hours of treatment.
1.Introduction
Virtually every patient admitted into ICU is administered
analgesia and sedation therapy. Therefore, sedation and pain
control are crucial in the management of intensive care unit
(ICU)patients.Because ofthemultiplicityofpatientsadmit-
ted to ICU, it is diﬃcult to deﬁne a standard procedure for
ICU sedation. One may encountera variety of pathologies of
diﬀerent grades of severity; in addition, the associated mor-
bidity, the circulatory instability, and the pharmacodynamic
alterationsin critically ill patientscanmake treatment guide-
line diﬃcult to establish and implement [1]. Precise control
of the depth of sedation is often not well managed; patients
are frequently over- or undersedated with an accompanying
increase in morbidity, mortality, and economic cost.
The provision of eﬀective analgesia and sedation for pa-
tients in ICU is important in controlling pain, dyspnea, and
delirium; relieving agitation and anxiety; decreasing oxygen
consumption; providing amnesia; preventing seizure; main-
taining brain function; applying neuromuscular blockage;
aiding compliance with mechanical ventilation; thereby
maintaining patient comfort [2–4]. Agents such as propofol
and midazolam are commonly used for sedation in ICU
because of their eﬀectivenessand relatively short elimination
half-lives. The risk for accumulation and delayed recovery
with these agents appears to be lower than that with tradi-
tional opioids. Consequently, opioid dose is usually mini-
mized, with clinicians choosing to manipulate the sedative
dose to maintain optimal patient comfort. On the other
hand, analgesia-based sedation techniques, which focus on
patient comfort rather than on patient sedation by catering
to the analgesic needs of the patient and adding a sedative
only if necessary, have become more established in the ICU
setting. Both approaches currently have certain limitations
[3], because when administered over several hours or even
days, elimination of most drugs used for analgesia and se-
dation may be reduced in critically ill patients secondary to
impairment in organ-dependent elimination. This can result
in delayed emergence from sedation after discontinuation of
administration, increased time on the ventilator and in ICU,
and therefore increased costs. Moreover, prolonged sedation
may not only have economic consequences but also medical
ones, such as failure to recognize cerebral insult, immuno-
suppression, or venous stasis leading to thromboembolism2 Pain Research and Treatment
[1]. A specialized ICU team, including physicians, nurses,
and pharmacists, has important responsibilities in maximiz-
ing the clinical eﬀect of medicines, minimising the risk of
treatment-induced adverse events, and minimising the ex-
penditures for pharmacological treatments. [5].
In this study, we aimed to assess the quality of sedoanal-
gesia and outcome parameters in regimens containing either
fentanyl or remifentanil.
2.Methods
2.1. Study Population and Study Center. This study was a
prospective, randomized, open-label, and controlled trial
approved by the Research Ethics Committee of Ministry of
Health G¨ oztepe Research & Teaching Hospital in Istanbul,
Turkey. This trial was conducted in the 16-bed capacity ICU
of the above-mentioned hospital. This study was carried
out over a period between September 1, 2007 and May
31, 2008. Thirty-four patients were included in the study,
and the patients were randomly allocated to one of two
groups. All of the patients were provided with mechanical
ventilation by Simultaneously Intermediate Mechanical Ven-
tilation/Volume Control (SIMV/VC) mode.
2.2. Eligibility Criteria
2.2.1. Inclusion Criteria. Age ≥ 18; patient requiring me-
chanical ventilation and sedation.
2.2.2. Exlusion Criteria. Age ≤ 18; patients who have neuro-
muscular disease; patients who are receiving neuromuscular
blockers; patients with a known or suspected allergy or
intolerance to midazolam, fentanyl, or remifentanil; patients
who die during the study period; patients who use toxic
substances; alcoholic patients; patients suspected of being
pregnant; patients who are moribund, that is, who are
classiﬁed as ASA grade V according to the American Society
of Anesthesiologists (not expected to live > 24 hours).
Because most patients were transferred to ICU from
brain surgery theatre and were thus already sedated on ad-
mission, the WHO chronic pain was not reckoned to be
applicableas an exclusion criterion. By the same token,given
the patient groupinvestigated in this study, confusion assess-
ment was not deemed necessary.
2.3. Drugs and Infusion Regimens. Remifentanil (5mg), fen-
tanyl (10mg), and midazolam (60mg) were diluted with
0.9% sodium chloride (150mL). The concentration of
remifentanil solution was 0.03mg/mL, fentanyl solution
0.06mg/mL, and midazolam solution 0.4mg/mL. In total,
34 patients were randomized to receive either a remifentanil-
midazolam regimen (R group, n = 17) or a fentanyl-
midazolam regimen (F group, n = 17), for analgesia and
sedation in the ICU. The R group received remifentanil
at an initial dose of 0.05µg/kg/min, and the F group re-
ceived fentanyl at an initial dose of 0.015µg/kg/min. Both
groups received midazolam infusion at an initial dose of
0.03mg/kg/h (see Figure 7).
No adjuvant analgesics such as paracetamol or morphine
were administered, andno rescuepain therapywasprovided.
Bolusdosesof remifentanil, fentanyl, or midazolam were not
allowed in the protocol and therefore were not administered.
2.4. Measurement Scales. In many government hospitals in
Turkey, such as the center where the study was performed,
there is no written protocol governing the use of agents pro-
viding sedoanalgesia; physicians tend to rely on their clinical
experience and an assessment of the patient’s hemodynamic
status to determine doses. In this study, however, in order to
maintain an adequate level of sedoanalgesia, an RS score of
t h r e eo rl e s s( ≤3) was reckoned to warrant an incremental
increase in the opioid maintenance dose. In the F group an
increase in fentanyl by 0.01µg/kg/min and in the R group an
increaseinremifentanilby0.05µg/kg/minwereadministered
(Figure 7).
After the protocol was initiated, daily interruption of
analgesia and sedation was performed. Once this daily
interruptionprocedurewas completed,thedosagesofopioid
analgesics and sedative were readjusted in the light of the
patients’ needs, as described above. This daily procedure
was continued until analgesia-based sedation therapy was
no longer required. GCS and APACHE II scores were used
to assess level of consciousness of patients and also severity
of their diseases. The use of GCS was judged appropriate
because most patients were referred from the brain surgery
service.
2.5. Measurements and Records. The patients’ demographic
data and medical history, and also details of their physical
examination, were recorded before starting sedation and
analgesia therapy. APACHE II score and GCS were recorded
daily in order to assess the seriousness of the patients’
condition. Unless speciﬁed, the following parameters were
recorded every two hours on the ﬁrst day of admission and
every six hours thereafter: scores of RS and SAS (in order to
assess the quality of sedation); BPS score (to assess quality of
analgesia);invasiveBP,CVP,HR,bodytemperature(toassess
hemodynamic status and organ dysfunction—performed
hourly throughout the study); PaCO2,P a O 2,S p O 2,a n d
pH (lung function assessment); ALT and AST (for hepatic
function), BUN and SrCr (renal function measurement).
The total daily doses of remifentanil, fentanyl and also
midazolam were recorded daily. In addition, the time to
tracheal extubation after sedation interruption, time to
ICU discharge, and time of stay in ICU were recorded.
Furthermore, adverse drug reactions and also the use of
agents used to treat these side eﬀects were documented.
2.6. Statistical Analysis. All the variables are expressed as
mean ± SD. Diﬀerences between groups were assessed using
mixed-design ANOVA (one way for independent groupsand
repeated measures) with post hoc Scheﬀe’s test. Correlation
coeﬃcients were calculated using Pearson correlation anal-
ysis. A value of P<0.05 in a two-tailed distribution was
considered statistically signiﬁcant. All signiﬁcant diﬀerences
used in this paper were further subjected to power analysis.Pain Research and Treatment 3
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Figure 1:Meanarterial pressure (mmHg) in F andR groups before
induction (basal) and during the ﬁrst 48 hours of the sedation and
analgesia therapy (P>0.05) (mean ± SD).
3.Results
3.1. Demographics. A total of 34 patients were enrolled in
the study, of which 32 were able to be evaluated. Two
patients (one patient in the fentanyl/midazolam group and
one patient in the remifentanil/midazolam group) had to be
excluded because they died before weaning during the study.
The baseline characteristics of the 32 patients included in
the study are summarized in Table 1.T h es m a l ln u m b e ro f
subjects and the heavy proportion of neurosurgical patients
can be explained by the fact that the ICU was a referral
centre for postoperative brain surgery patients such as those
with spinal and brain tumours, intracerebral aneurysms,
intracranial abscesses, and hematomas. In addition, during
the study period the ICU was temporarily closed for some
pressing repair work on the fabric of the unit.
There were no signiﬁcant diﬀerences between the groups
with respect to baseline hemodynamic parameters and also
demographic data (P>0.05).
3.2. Hemodynamics. With respect to MAP, there was no
signiﬁcant diﬀerences observed between the F and R groups
(P>0.05). However there were signiﬁcant variations in
MAP within each group, during the course of time. For
example, within both groups a signiﬁcant fall in MAP was
observed in the ﬁrst six hours after sedation was initiated
(P<0.05).Inaddition,ascanbeseenin Figure 1,duringthis
period the R group demonstrated a greater, but statistically
nonsigniﬁcant, reduction in MAP than the F group.
In regard to HR, there were no signiﬁcant diﬀerences
between the F and R groups at baseline (P>0.05). How-
ever, in the ﬁrst six hours after analgosedation was initiated,
Table 1:Demographicandclinicalcharacteristics ofthepatientson
admissionto ICU.
Variables R group
(n = 16)
F group
(n = 16) P value
Age, yr 50.63 ± 25.24 51.88 ± 20.77 0.985
Weight, kg 65.94 ± 11.89 70.06 ± 15.12 0.539
Gender∗
M7 1 0
F9 6
Clinic∗
Brain surgery 13 12
Internal 1 1
General surgery 1 0
Urology 0 1
Orthopaedics 1 2
APACHE II score 9.56 ± 3.83 11.94 ± 6.4 0.305
Pred. Mortality, % 12.3 ± 7.73 17.18 ± 14.4 0.243
GCS 11 ± 3.97 10.06 ± 4.74 0.669
MAP, mmHg 96.25 ± 17.43 86.63 ± 19.18 0.254
Heart rate, beats/min 93 ± 17.92 86.75 ± 25.17 0.305
Temperature, ◦C 36.5 ± 0.54 36 ± 0.47 0.080
sPO2,% 9 9± 0.89 97.63 ± 4.88 0.696
PaO2, mmHg 167.63 ± 57.38 199.3 ± 95.22 0.287
PaCO2, mmHg 36.78 ± 7.96 37,14 ± 11,36 0.867
PH 7.37 ± 0.1 7.34 ± 0.12 0.381
CVP, mmHg 7.13 ± 3.86 8.38 ± 6.45 0.780
ALT, U/L 68.38 ± 65.93 37.31 ± 28.85 0.067
AST, U/L 135.93 ± 316.02 38.5 ± 22.06 0.305
BUN,mg/dL 42.75 ± 29.52 61.81 ± 79.38 0.985
SrCr,mg/dL 0.8 ± 0.3 1.35 ± 0.63 0.361
∗Because the ﬁgures involved in these categories were small, statisticalanal-
ysis was not deemed necessary.
as i g n i ﬁ c a n td i ﬀerence in HR was observed between the
groups (P<0.05). During this time, as can be seen in
Figure 2, remifentanil caused a sharp reduction in HR, while
the HR of patients receiving fentanyl remained relatively
stable.
There was no signiﬁcant diﬀerences between the F and R
groups (P>0.05) in terms of body temperature.
3.3. Analgesics and Sedative Dosage. Daily interruption was
performed in order to provide controlled sedation and
analgesia. In addition, doses of midazolam, fentanyl, and
remifentanil were titrated according to patients’ require-
ments and hemodynamics. The mean daily administered
dosages of fentanyl and remifentanil were 18.41 ± 2.87mg
(range 0.015 to 0.03µg/kg/min) and 4.97 ± 1.31mg (range
0.05 to 0.1µg/kg/min), respectively (see Figure 3). Only the
ﬁrst four days of sedoanalgesic treatment were recorded4 Pain Research and Treatment
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Figure 2: Mean heart rate (beats/min) in F and R groups before
induction (basal) and during the ﬁrst 48 hours of the sedation and
analgesia therapy (P>0.05).
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Figure 3: Total daily analgesic dosage (mg) of the patients in F and
Rgroups ondays 1,2,3, and4ofthesedationandanalgesiatherapy
(P>0.05).
because after this the patients’ sedoanalgesia was terminated
in preparation for discharge (see Figure 6). If sedoanalgesia
treatment lasted less than four days, no patient data for the
period after stopping sedoanalgesia was recorded.
The mean daily administered dosages of midazolam in
the F group were 90.62 ± 25.58mg (range 0.03 to 0.09mg/
kg/h) and in the R group were 96.54 ± 26.05mg (range 0.03
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Figure 4: Total daily midazolam dose (mg) of patients in F and R
groups on days 1, 2, 3, and 4 of the sedation and analgesia therapy
(P>0.05).
Table 2: Mean daily RS and SAS scores during the study period.
n = 32 RS SAS R value
Day 1 5.70 1.55 −0.744
Day2 5.00 2.30 −0.926
Day3 4.59 2.80 −0.648
Day4 3.80 3.58 −0.357
to 0.12mg/kg/h). With respect to analgesic dos-ages, there
were no signiﬁcant diﬀerences between the F and R groups
(P>0.05), but signiﬁcant diﬀerences were found within the
groups (P<0.05) (see Figure 4). The midazolam require-
ments in the F group were lower than those in the R group.
However, this ﬁnding was not statistically signiﬁcant.
3.4. Quality of Sedation and Analgesia. As can be observed
in Table 2, at the induction of sedation, the mean RS for F
and R groups was between 4 and 5, while the mean SAS for
both groups was between 2 and 3. There were no signiﬁcant
diﬀerences between the groups (P>0.05). On the other
hand, therewasastrong negativecorrelationbetweenRSand
SAS (R = 0.822, P<0.001) (Figure 5).
Attheinductionofsedation(baseline), the meanBPSfor
F and R groups was between 3 and 4 which indicate “mild
to moderate pain.” At baseline, there were no signiﬁcant
diﬀerences between the groups (P>0.05). While in both
groups the BPS scores resembled each other before opioid
induction, after analgesic therapy was initiated a signiﬁcant
reduction was recorded compared with baseline values (P<
0.001). In comparison with the F group, the R group pro-
vided a signiﬁcantly greater reduction in the ﬁrst 10 minutes
(P<0.05).Pain Research and Treatment 5
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Figure 5: Correlation between RS and SAS in patients sedated with
midazolam during the four days of sedoanalgesia (R =− 0.822, P<
0.001).
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Figure 6: Time of sedation, mechanical ventilation, and ICU
discharge (hours) in F and R groups.
The mean sedation times within F and R groups were
48.56 ± 32.7 and 54 ± 21.19 hours (P>0.05), respectively.
There were no signiﬁcant diﬀerences within either group
(P>0.05) or between groups (Figure 6).
The mean mechanical ventilation times of the F and R
groups were 45.75 ± 47.13 and 45.75 ± 74.71 hours (P>
0.05). Regarding mechanical ventilation time, there were no
statistically signiﬁcant diﬀerences between both groups (P>
0.05) (see Figure 6).
The mean times toICUdischarge of F and R groupswere
237 ± 159.89 hours and 208.69 ± 239.06 hours (P>0.05),
Table 3: BUN and creatinine data in F and R groups at 0, 24, 48,
72, and 96 hours.
Hours Group F
(n = 16)
Group R
(n = 16) P value
BUN
0 32.51 ± 6.14 37.31 ± 23.75 > 0.05
24 30.81 ± 13.2 37.06 ± 24.45 > 0.05
48 28.62 ± 14.01 36.56 ± 24.23 > 0.05
72 29.56 ± 16.10 31.25 ± 18.90 < 0.05
96 28.80 ± 16.24 26.38 ± 17.74 < 0.05
SCr
02 . 2 8 ± 4.47 0.80 ± 0.30 > 0.05
24 2.05 ± 4.16 0.78 ± 0.35 > 0.05
48 1.61 ± 2.47 0.75 ± 0.34 > 0.05
72 1.54 ± 2.42 0.75 ± 0.33 > 0.05
96 1.52 ± 2.41 0.73 ± 0.31 > 0.05
respectively. With regard to ICU discharge time, there were
no signiﬁcant diﬀerences between groups statistically (P>
0.05). However, as can be seen in Figure 6, there was a non-
signiﬁcant diﬀerence between groups, with the time until
ICU discharge of the R group being shorter than that of the
F group.
3.5. Organ Dysfunction. With respect to arterial blood gas
data, there were no signiﬁcant diﬀerences between the F and
R groups at 0, 24, 48, 72, or 96 hours (P>0.05), but
regarding PaO2,s i g n i ﬁ c a n td i ﬀerences were found within
both groups at 24 and 48 hours (P = 0.015 and P =
0.017, resp.) Concerning plasma pH, there were signiﬁcant
diﬀerences within both groups at 24 and 48 hours (P =
0.013 and P = 0.014, resp.). In addition, regarding SpO2,
signiﬁcant diﬀerenceswere found withinbothgroupsat time
0a n d2 4h o u r s( P = 0.016 and P = 0.018, resp.). With
respect toPaCO2,therewere no signiﬁcant diﬀerenceswithin
the groups at time 0, 24, 48, 72, or 96 hours (P>0.05).
Regarding BUN, an examination of Table 3 shows that
there were no signiﬁcant diﬀerences between either group at
0,24,or48hours(P>0.05).However,signiﬁcantdiﬀerences
were found between both groups at 72 and 96 hours (P =
0.014 and P = 0.021, resp.). The ﬁnding relating to the
diﬀerence in BUN at 96 hours had a high power value of
0.991 according to power analysis. With respect to serum
creatinine, signiﬁcant diﬀerences were not observed either
within or between the groups at 0, 24, 48, 72, and 96 hours
(P>0.05).
As can be seen in Table 4, with respect to ALT, signiﬁcant
diﬀerences were not found between the groups at 72 or 96
hours (P>0.0 5 ) .H o w e v e r ,t h e r ew e r es i g n i ﬁ c a n td i ﬀerences
between both groups at times of 0, 24, and 48 hours (P =
0.015, P = 0.029, and P = 0.021, resp.). Concerning AST,
signiﬁcant diﬀerences were not observed between the groups
at 0, 24, 48, 72, or 96 hours (P>0.05).
3.6. Adverse Eﬀects. The blood pressure of one patient in the
F group and two patients in the R group, all of whom had a
preexisting comorbidity of chronic hypertension, could not6 Pain Research and Treatment
Table 4: Liver enzyme data in F and R groups at 0, 24, 48, 72, and
96 hours.
Hours Group F
(n = 16)
Group R
(n = 16) P value
ALT
0 37.31 ± 31.25 68.38 ± 65.93 < 0.05
24 41.06 ± 28.25 65.81 ± 62.52 < 0.05
48 42.53 ± 25.15 48.80 ± 36.90 < 0.05
72 39.13 ± 19.20 43.25 ± 30.70 > 0.05
96 34.44 ± 12.32 42.25 ± 26.72 > 0.05
AST
0 38.50 ± 22.06 45.38 ± 28.23 > 0.05
24 40.01 ± 22.75 44.06 ± 23.64 > 0.05
48 41.44 ± 17.36 38.50 ± 19.39 > 0.05
72 42.81 ± 21.65 39.01 ± 18.48 > 0.05
96 42.75 ± 19.67 46.38 ± 31.09 > 0.05
be well controlled. Esmolol or nitroprusside infusions were
administered to these patients in order to keep their blood
pressure within the normal range.
Bycontrast,hypotensionwasobservedin5patientswith-
in the F group. Therefore, dopamine + dobutamine + nora-
drenaline IVinfusion wasstarted in 2patients,while dopam-
ine + dobutamine iv infusion was administered in the other
3 patients to manage their hypotension. Hypotension was
also observed in 5 patients within the R group. Two of these
patients were treated with dopamine + noradrenaline infu-
sion, and the other 3 patients were treated with dopamine +
dobutamine infusion. There was no signiﬁcant diﬀerence
between the F and R groups statistically (P>0.05).
Bradycardia was observed in 2 patients, both from the
R group. This problem was managed using 0.5mg atropine.
Apart from hypotension and bradycardia, no other side
eﬀects were observed in either group. There was no recorded
clinical evidence to suggest the development of delirium or
tolerance to remifentanil or fentanyl.
4.Discussion
4.1. Sedation Protocols. W h e r et h ep r i m a r yg o a li st oa c h i e v e
the earliest awakening possible a sedation protocol strategy
which includes daily interruption of sedative infusions may
be applied [6]. In addition, daily arousal can help to deal
with the unpredictability of sedation levels and reduce the
amount of sedative drug needed. Daily interruption of
sedative in mechanically ventilated patients decreases the
duration of mechanical ventilation and the length of stay
in the ICU. It may also reduce many of the complications
associated with sedatives and result in improved clinical
outcomes [7]. Most interestingly, no subsequent negative
long-term psychological eﬀects are observed in patients who
have been assessed on a daily basis. Moreover, long-term
followup suggests that posttraumatic stress disorders are less
pronounced compared to the control group [8].
Protocols aimed at reducing the adverse eﬀects of seda-
tion through close monitoring and selection of agents with
lower accumulative potential have proven particularly suc-
cessful in critically ill patients requiring prolonged ventila-
tory support [9].
4.2. Hemodynamics. Similar to the research of Akıncı et
al. [10], in our study there were no signiﬁcant diﬀerences
between the F and R groups in terms of MAP, HR, or body
temperature. On the other hand, the R group demonstrated
a greater, but statistically non-signiﬁcant, reduction in MAP
than the F group (Figure 1). The similarity in the weighted
mean body temperature, MAP, and HR data and the
comparableincidenceofpatientswithhemodynamicoutliers
inbothtreatmentgroupsshowthatremifentanilandfentanyl
both provided an acceptable degree of hemodynamic stabil-
ity [10, 11]. In contrast, a study comparing bolus remifen-
tanil with fentanyl (both at 2µg/kg) in children suggested
that remifentanil lowered blood pressure, heart rate, and the
rate pressure product (heart rate + systolic blood pressure)
signiﬁcantly more than fentanyl, after anaesthetic induction.
In two of the patients, remifentanil induced bradycardia
requiring atropine intervention [12].
4.3. Analgesics and Sedative Dosage. Breenet al. [13]d e m o n -
strated that midazolam requirements were considerably
reduced in the remifentanil group compared to fentanyl and
were relatively constant throughout the treatment period.
They postulated that this was a reﬂection of the hypnotic-
agent sparing eﬀects of remifentanil and the ease with which
the infusion couldbe titrated toobtainoptimumcomfort.In
our study, there were no signiﬁcant diﬀerencesin midazolam
dosage requirement between the F and R groups (P>0.05),
although a nonsigniﬁcantly lower midazolam requirement
in the F group compared to the R group was observed
(Figure 4). In addition, the dose of remifentanil could not
be increased easily because of its potential bradycardia eﬀect.
Therefore, the dosage of remifentanil was increased cau-
tiously to obtain optimum patient comfort. A study among
patients undergoing surgery for abdominal-aortic aneurysm
indicated that remifentanil may provide more stable pain
control than the combination of fentanyl-midazolam [14].
This proposal was not substantiated by our study.
4.4. Quality of Sedation and Analgesia. In our study, mid-
azolam-induced sedation was assessed by validated RS and
SAS. Riker et al. demonstrated good validity and reliability
with SASand a good correlation betweenthe SASand the RS
[15].Inourstudyalso,astrong,negativecorrelationbetween
RS and SAS was observed (R = 0.822, P<0.001) (Figure 6),
while there were no signiﬁcant diﬀerences between the
groups (P>0.05).From the induction of sedation, the mean
RSs for the F and R groups were between 4 and 5, while
the mean SAS for both groups was observed to be between
2 and 3. These sedation scores may also indicate that patients
were at times oversedated. On the other hand it should be
noted that 81% of the patients in the R group and 75%
of the patients in the F group were neurosurgical patients.
Karabinis et al. assessed the safety and eﬃcacy of analgesia-
based sedation using remifentanil in a neurointensive carePain Research and Treatment 7
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Allocation
Allocated to R intervention (n = 17)
♦Received allocated intervention (n= 16)
idazolam m0 .03mg/kg/h
Did not r
r
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r
eceive allocated intervention (n = 1)
1patient died
Monitoring
Analysed (n = 16)
Mixed-design ANOVA Mixed-design ANOVA
Post hoc Sche e’s test
Power analysis
Analysis
♦
Discontinued intervention (n = 0)
If Rams s ey cale ≤ 3, remifentanil dose
increased by 0.05
RS, SAS, GCS, APACHE II, organ
functions, hemodynamic
parameters
Discontinued intervention (n = 0)
If Ramsey scale ≤ 3, fentanyl dose increased
by 0.01 g/kg/min µ µ g/kg/min
♦Initial Dose: emifentanil 0.05µ µ g/kg/min
Figure 7: Study algorithm.
unit,andthemeanSASscorewasobservedtobebetweenone
and three. They also did not observe any clinical diﬀerences
in either pain or sedation scores [11]. In addition, they
suggested that additional daily neurological assessments,
such as measuring intracranial pressure (ICP) and cerebral
perfusion pressure (CPP), should be undertaken in order to
provide adequate sedation.
After analgesic therapy was initiated, a signiﬁcant reduc-
tion in BPS scores was recorded compared with baseline
values (P<0.001). In comparison with the F group, the R
groupprovidedasigniﬁcant reductionintheﬁrst 10minutes
(P<0.05). Similar to our study, Akıncı et al. observed that
fentanyl caused signiﬁcant reduction in BPS score within
10 minutes of infusion while remifentanil achieved a similar
reduction within 5 minutes (P<0.05) [10]. Our study
conﬁrms ﬁndings suggesting that remifentanil has a more
rapid onset of action than fentanyl [10].
With reference to mechanical ventilation and ICU dis-
charge time, sedation and analgesia scales play an important
role in providing optimum sedoanalgesia. Botha and Mud-
holkar found that the introduction of a sedation scale led to
a reduction in the duration of mechanical ventilation [16].
Breen et al. demonstrated a decrease in the duration
of mechanical ventilation when using remifentanil-based
analgesia and sedation [13], while Amor et al. observed that
the extubation time of remifentanil was shorter than that8 Pain Research and Treatment
for fentanyl [17]. By contrast Akıncı et al. [10]a n dK a r a -
binis et al. [11] found no diﬀerence between remifentanil
andfentanylgroupsconcerningtimetoextubation.Likewise,
in our study, with respect to sedation and mechanical ven-
tilation time, there were no signiﬁcant diﬀerences between
groups (P>0.05) (see Figure 6).
Breen et al. [13] also observed that there was a non-
signiﬁcant trend towards a shorter ICU stay in the remifen-
tanil group by one day. This is consistent with our study, as
can be seen in Figure 6, where the ICU discharge time of the
R group is approximately one day lower than that of the F
group (P>0.05). The trend towards reduced duration of
ICU stay is supported by the work of Matthey et al. [18],
who showed that remifentanil-based sedation signiﬁcantly
reduced the time on mechanical ventilation and allowed
earlier discharge from the ICU than fentanyl-based sedation.
4.5. Organ Dysfunction. The shorter weaning time with
remifentanil is a direct consequence of its pharmacoki-
netic proﬁle. Remifentanil has a rapid onset (1 minute)
and oﬀset (half life < 10 minutes) of action [19]. Its organ-
independent metabolism by nonspeciﬁc blood and tissue
esterases results in a pharmacokinetic proﬁle unaﬀected by
impaired kidney [17]a n dl i v e r[ 20] function. It does not
accumulate, even after prolonged infusion [21]. Although
fentanyl has a rapid onset and a short clinical duration with
single doses, accumulation and prolonged sedative eﬀects
may be observed after continuous administration. In our
study, there were signiﬁcant diﬀerences between the R and
F groups at times of 0, 24, and 48 hours (P<0.05) with
r e s p e c tt oA L T .A ss h o w ni nTable 4,A L Tl e v e lw a sd e c r e a s e d
in R group while it was increased in F group within the
ﬁrst 48 hours. In terms of BUN levels (Table 3), we found
signiﬁcant diﬀerences between both groups at 72 and 96
hours (P<0.05). Clinically there may be little diﬀerence
between the groups, but its organ-independent mode of
metabolism makes remifentanil the opioid of choice for use
in patients with impaired renal or hepatic functions.
4.6.AdverseEﬀects. Withrespecttoadverseeventsduringthe
provision of adequate sedation and analgesia, no statistically
signiﬁcant diﬀerences could be determined [11, 13]. An
in-vivo study observed no signiﬁcant diﬀerences between
remifentanil, fentanyl, and isoﬂurane in terms of motor
function, anaesthetic time required for the amplitude of the
third negative postsynaptic (N3) wave to disappear, or in
the numbers of morphologically normal-appearing neurons
seven days after reperfusion. The researchers demonstrated
that high-dose fentanyl and remifentanil do not exacerbate
ischaemic spinal cord injury. This may be a signiﬁcant
ﬁnding because many patients in ICU such as those in our
study have sustained CNS damage [22].
The highest incidence of drug-related adverse eﬀect in
the R and F groups was related to hypotension. When
hypotension occurred it was controlled ﬁrstly by titration
of opioid dose, and then, when necessary, by the use of
inotropessuchasdopamineand/ordobutamine.Inaddition,
bradycardia was observed in two patients from the R group,
and was managed using atropine. Our ﬁndings indicate that
remifentanil and fentanyl have similar adverse eﬀect proﬁles.
4.7. Clinical Pharmacy Services in ICU. Recent studies have
reported that clinical pharmacy services can reduce hospital
mortality rates [23], preventable adverse drug events [24],
and medical costs [25]a n di m p r o v et h ee ﬃcacy of treatment
[26]. In addition, it has been demonstrated that the insti-
tution of a daily pharmacist-enforced intervention directed
at improving sedation guideline adherence resulted in a
signiﬁcant decreasein thedurationofmechanical ventilation
in patients receiving continuous sedation [27].
5.Conclusion
Inconclusion,thisstudydemonstratesthattherewereasmall
number of signiﬁcant diﬀerences between remifentanil and
fentanyl statistically with respect to hemodynamic param-
eters, analgesic and sedative requirements, sedation time,
mechanical ventilation time, ICU discharge time, organ dys-
function, or adverse eﬀects. Compared to fentanyl, remifen-
tanil provided signiﬁcantly more potent and rapid anal-
gesia based on BPS measurements and a statistically non-
signiﬁcantly shorter time to discharge. On the other hand,
remifentanil caused a signiﬁcantly sharper fall in heart rate
within the ﬁrst six hours of treatment. Differences between
groups in terms of BUN and ALT were also recorded.
Although both fentanyl-midazolam and remifentanil-mid-
azolam can safely provide sedation and analgesia, ﬁne
diﬀerences between the fentanyl and remifentanil should be
considered when selecting a suitable regimen for individual
patients.
The employment of sedation and analgesia assessment
scales such as SAS,RS,and BPS is useful to provideoptimum
sedation and analgesia. A strong correlation between SAS
and RS was found in this study which conﬁrms the value of
these measurement criteria. These tools should therefore be
utilized by the ICU team to ensure the patient is comfortable
without being oversedated.
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